Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0T9DN
|
||||
| Former ID |
DIB010539
|
||||
| Drug Name |
Dimiracetam
|
||||
| Synonyms |
BND-11624; Dimiracetam, Neurotune; NT-11624; NMDA receptor antagonist (oral, neuropathic pain/osteoarthritic pain), Neurotune
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Neuropathic pain [ICD9: 356.0, 356.8; ICD10:G64, G90.0] | Phase 2 | [1] | ||
| Company |
Brane Discovery Srl
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C12H16N4O4
|
||||
| Canonical SMILES |
N12C(NC(=O)C2)CCC1=O
|
||||
| CAS Number |
CAS 126100-97-8
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | NMDA receptor | Target Info | Antagonist | [2] | |
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01135251) Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy. U.S. National Institutes of Health. | ||||
| REF 2 | Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Neuropharmacology. 2014 Jun;81:85-94. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.